
    
      A randomized, single-blind, multicenter, Phase 3 study of IV and/or oral tedizolid phosphate
      200 mg once per day for 6 days compared with IV and/or oral comparator for 10 days for the
      treatment of cSSTI, also known as acute bacterial skin and skin structure infections, in
      participants 12 to <18 years. cSSTI includes major cutaneous abscess, cellulitis/erysipelas,
      and wound infection.
    
  